Tesamorelin

FDA Approved

Tesamorelin

Category
Growth Hormone
Aliases
Egrifta, Egrifta SV
Administration
Subcutaneous injection (once daily)

Research and regulatory

Development stage

FDA approved (Egrifta, 2010) for reduction of excess abdominal fat in HIV-associated lipodystrophy.

Legal and regulatory

FDA approved — Egrifta SV, for HIV-associated lipodystrophy. Off-label use for other purposes is not FDA-sanctioned.

Side effects

Injection site reactions, joint pain, peripheral edema, potential blood sugar elevation